Dual orexin receptor antagonists (DORAs) are the first novel mechanism approved for primary insomnia since the Z-drugs (zolpidem, eszopiclone, zaleplon) entered the market in the 1990s. Three are FDA-approved as of 2026: suvorexant (Belsomra,…